TriSalus Life Sciences, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
TriSalus reported Q2 2026 revenue of $11.4 million (flat YoY, +1.7%), with gross margins improving to 86.8% from 83.9%. Operating losses widened to $9.8 million from $7.3 million due to sales/marketing expansion, despite lower R&D and G&A. The company maintains full-year 2026 revenue guidance of $54–57 million (19–26% growth vs. 2025), holds $46.3 million in cash after a $46 million Q1 equity raise, and reports expanded commercial operations. CMS recently established a G-code for pressure-generating catheter reimbursement.
Why this rating
Flat revenue growth, widening losses, and execution-dependent guidance represent ordinary business progress. While $46M cash provides runway, losses and dilution offset clinical/regulatory wins. Event is routine for early-stage medtech.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.